​

Pfizer (PFE) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

PFE Stock Forecast

Pfizer (PFE) stock forecast, based on 39 Wall Street analysts, predicts a 12-month average price target of $27.60, with a high of $35.00 and a low of $25.00. This represents a 6.36% increase from the last price of $25.95.

$25 $27 $29 $31 $33 $35 High: $35 Avg: $27.6 Low: $25 Last Closed Price: $25.95

PFE Stock Rating

Pfizer stock's rating consensus is Hold, based on 39 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 16 Buy (41.03%), 21 Hold (53.85%), 2 Sell (5.13%), and 0 Strong Sell (0.00%).

Hold
Total 39 2 21 16 0 Strong Sell Sell Hold Buy Strong Buy

PFE Price Target Upside V Benchmarks

TypeNameUpside
StockPfizer6.36%
SectorHealthcare Stocks 15.45%
IndustryDrug Manufacturers - General Stocks11.43%

Price Target Trends

1M3M12M
# Anlaysts1416
Avg Price Target$26.00$27.00$27.75
Last Closing Price$25.95$25.95$25.95
Upside/Downside0.19%4.05%6.94%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
May, 2629151229
Apr, 2628151228
Mar, 2628151228
Feb, 2637151-26
Jan, 2637151-26
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 14, 2026Alexandria HammondWolfe Research$26.00$25.960.15%0.19%
Mar 17, 2026Terence FlynnMorgan Stanley$27.00$27.06-0.22%4.05%
Mar 09, 2026Evan David SeigermanBMO Capital$30.00$26.4913.25%15.61%
Feb 24, 2026Trung HuynhRBC Capital$25.00$27.14-7.89%-3.66%
Feb 19, 2026Emily FieldBarclays$25.00$26.86-6.92%-3.66%
Feb 12, 2026Narumi NakagiriDaiwa$27.00$27.73-2.63%4.05%
Jan 27, 2026Cantor Fitzgerald$27.00$25.884.33%4.05%
Jan 06, 2026UBS$25.00$25.43-1.69%-3.66%
Dec 17, 2025Alexandria HammondWolfe Research$24.00$25.53-5.99%-7.51%
Dec 12, 2025Morgan Stanley$28.00$25.898.15%7.90%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 14, 2026Wolfe ResearchUnderperformUnderperformhold
Apr 29, 2026CitigroupNeutralNeutralhold
Apr 16, 2026CICCOutperforminitialise
Mar 24, 2026GuggenheimBuyBuyhold
Mar 17, 2026Morgan StanleyPositivePositivehold
Mar 09, 2026BMO CapitalOutperformOutperformhold
Feb 24, 2026RBC CapitalSector PerformUnderperforminitialise
Feb 19, 2026BarclaysEqual-WeightUnderweightinitialise
Feb 12, 2026DaiwaOutperformNeutraldowngrade
Jan 27, 2026Cantor FitzgeraldNeutralNeutralhold

Financial Forecast

EPS Forecast

$0 $1 $2 $3 $4 $5 $6 $7 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$3.95$5.59$0.38$1.42$1.36---
Avg Forecast$4.21$6.50$1.55$2.92$2.91$3.01$2.98$2.85
High Forecast$4.35$6.64$1.66$3.12$3.03$3.92$3.37$2.91
Low Forecast$4.06$6.29$1.48$2.73$2.46$2.58$2.24$2.77
Surprise %-6.18%-14.00%-75.48%-51.37%-53.26%---

Revenue Forecast

$55B $65B $75B $85B $95B $105B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$81.29B$100.33B$59.55B$63.63B$62.58B---
Avg Forecast$81.76B$100.34B$58.78B$63.08B$63.08B$63.06B$62.33B$59.90B
High Forecast$83.89B$101.97B$59.18B$63.63B$63.93B$63.14B$62.50B$60.82B
Low Forecast$79.56B$97.80B$58.53B$62.67B$62.46B$62.99B$62.17B$58.66B
Surprise %-0.58%-0.01%1.32%0.87%-0.79%---

Net Income Forecast

$0 $7B $14B $21B $28B $35B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$22.15B$31.36B$2.13B$8.02B$7.77B---
Avg Forecast$24.02B$18.44B$2.13B$16.71B$15.66B$18.56B$12.93B$16.27B
High Forecast$24.84B$22.12B$2.56B$17.81B$17.30B$22.37B$19.23B$16.59B
Low Forecast$23.18B$14.75B$1.71B$15.60B$14.02B$14.75B$12.79B$15.83B
Surprise %-7.82%70.12%-0.05%-52.00%-50.38%---

PFE Forecast FAQ

Is Pfizer stock a buy?

Pfizer stock has a consensus rating of Hold, based on 39 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 16 Buy, 21 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that Pfizer is a neutral investment for most analysts.

What is Pfizer's price target?

Pfizer's price target, set by 39 Wall Street analysts, averages $27.6 over the next 12 months. The price target range spans from $25 at the low end to $35 at the high end, suggesting a potential 6.36% change from the previous closing price of $25.95.

How does Pfizer stock forecast compare to its benchmarks?

Pfizer's stock forecast shows a 6.36% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the drug manufacturers - general stocks industry (11.43%).

What is the breakdown of analyst ratings for Pfizer over the past three months?

  • May 2026: 6.90% Strong Buy, 31.03% Buy, 51.72% Hold, 3.45% Sell, 6.90% Strong Sell.
  • April 2026: 7.14% Strong Buy, 28.57% Buy, 53.57% Hold, 3.57% Sell, 7.14% Strong Sell.
  • March 2026: 7.14% Strong Buy, 28.57% Buy, 53.57% Hold, 3.57% Sell, 7.14% Strong Sell.

What is Pfizer’s EPS forecast?

Pfizer's average annual EPS forecast for its fiscal year ending in December 2026 is $3.01, marking a 121.32% increase from the reported $1.36 in 2025. Estimates for the following years are $2.98 in 2027, and $2.85 in 2028.

What is Pfizer’s revenue forecast?

Pfizer's average annual revenue forecast for its fiscal year ending in December 2026 is $63.06B, reflecting a 0.78% increase from the reported $62.58B in 2025. The forecast for 2027 is $62.33B, and $59.9B for 2028.

What is Pfizer’s net income forecast?

Pfizer's net income forecast for the fiscal year ending in December 2026 stands at $18.56B, representing an 138.90% increase from the reported $7.77B in 2025. Projections indicate $12.93B in 2027, and $16.27B in 2028.